ibudilast 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antiasthmatics or antiallergics, not acting primarily as antihistaminics anti-allergic or anti-inflammatory, not acting as anti-histaminics 1406 50847-11-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ketas
  • KP-305
  • ibudilast
  • Molecular weight: 230.31
  • Formula: C14H18N2O
  • CLOGP: 3.41
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 34.37
  • ALOGS: -3.11
  • ROTB: 3

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
May 1, 1989 PMDA Kyorin Pharmaceutical

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Body tinea 278.99 232.36 44 940 1841 63486197
Inhibitory drug interaction 253.89 232.36 43 941 2806 63485232
Infection susceptibility increased 251.52 232.36 44 940 3477 63484561

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Body tinea 280.48 151.08 43 979 1811 79741555
Infection susceptibility increased 250.55 151.08 43 979 3678 79739688
Inhibitory drug interaction 236.18 151.08 42 980 4411 79738955
Glucose tolerance impaired 217.24 151.08 43 979 8041 79735325
Poor quality sleep 208.81 151.08 50 972 22672 79720694
Bone density decreased 195.74 151.08 43 979 13304 79730062
Impaired quality of life 192.53 151.08 43 979 14343 79729023
Purpura 189.88 151.08 45 977 19482 79723884
Impaired work ability 168.81 151.08 41 981 19640 79723726
Hyperlipidaemia 167.07 151.08 43 979 26050 79717316
Oral herpes 164.90 151.08 43 979 27411 79715955
Skin disorder 155.86 151.08 43 979 33900 79709466

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R03DC04 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Leukotriene receptor antagonists
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006401 Hematologic Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D010726 Phosphodiesterase Inhibitors
MeSH PA D010975 Platelet Aggregation Inhibitors
MeSH PA D019141 Respiratory System Agents
MeSH PA D014665 Vasodilator Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Asthma indication 195967001 DOID:2841




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.86 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
cAMP-specific 3',5'-cyclic phosphodiesterase 4B Enzyme IC50 7.19 CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4A Enzyme IC50 7.27 CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4D Enzyme IC50 6.78 CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4C Enzyme IC50 6.62 CHEMBL
Macrophage migration inhibitory factor Unclassified Kd 5.85 CHEMBL

External reference:

IDSource
D01385 KEGG_DRUG
C0123047 UMLSCUI
CHEBI:31684 CHEBI
CHEMBL19449 ChEMBL_ID
DB05266 DRUGBANK_ID
CHEMBL395091 ChEMBL_ID
3671 PUBCHEM_CID
C038366 MESH_SUPPLEMENTAL_RECORD_UI
7399 IUPHAR_LIGAND_ID
6068 INN_ID
M0TTH61XC5 UNII
010937 NDDF
AVL PDB_CHEM_ID

Pharmaceutical products:

None